Transcription of Intravenous Iron Therapy (NCD 110.10) - UHCprovider.com
{{id}} {{{paragraph}}}
Example: quiz answers
Intravenous Iron Therapy (NCD 110.10) - UHCprovider.com
Intravenous Iron Therapy (NCD ) Page 1 of 4 UnitedHealthcare Medicare Advantage Policy Guideline Approved 09/08/2021 Proprietary Information of UnitedHealthcare. Copyright 2021 United HealthCare Services, Inc. UnitedHealthcare Medicare Advantage Policy Guideline Intravenous Iron Therapy (NCD ) Guideline Number: Approval Date: September 8, 2021 Terms and Conditions Table of Contents Page Policy Summary .. 1 Applicable Codes .. 2 References .. 2 Guideline History/Revision Information .. 3 Purpose .. 3 Terms and Conditions .. 4 Policy Summary See Purpose Overview Iron deficiency is a common condition in end stage renal disease (ESRD) patients undergoing hemodialysis. Iron is a critical structural component of hemoglobin, a key protein found in normal red blood cells (RBCs) which transport oxygen.
Chapter 8; § 60.2.4 Intravenous Iron Therapy, § 60.2.4.2 Physician Billing Requirements to the Carrier. CMS Transmittal(s) Transmittal 10566, Change Request 12027, Dated 01/14/2021 (International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to National Coverage Determination (NCDs)--April 2021)
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: